OKYO Pharma Ltd ADR

OKYO Pharma Limited is a clinical-stage ophthalmology company based in London, United Kingdom, that develops therapies for corneal and anterior diseases. Its lead clinical product candidate, urcosimod, is in Phase 2 clinical trials for dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007.